Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · IEX Real-Time Price · USD
2.060
-0.020 (-0.96%)
At close: Jul 2, 2024, 3:56 PM
1.970
-0.090 (-4.37%)
After-hours: Jul 2, 2024, 4:00 PM EDT
Innate Pharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Innate Pharma stock has a target of 11.5, which predicts an increase of 458.25% from the current stock price of 2.06.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Innate Pharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +458.25% | Jun 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +458.25% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +458.25% | Apr 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +458.25% | Mar 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +458.25% | Nov 15, 2023 |
Financial Forecast
Revenue This Year
35.66M
from 61.64M
Decreased by -42.15%
Revenue Next Year
73.40M
from 35.66M
Increased by 105.84%
EPS This Year
-0.35
from -0.09
EPS Next Year
0.03
from -0.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 78.8M | 193.2M | 302.4M | 173.1M | 207.8M |
| Avg | 35.7M | 73.4M | 107.7M | 131.1M | 175.8M |
| Low | 6.9M | 6.9M | 20.6M | 68.4M | 138.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 27.8% | 441.8% | 312.0% | 60.7% | 58.5% |
| Avg | -42.2% | 105.8% | 46.7% | 21.7% | 34.1% |
| Low | -88.9% | -80.8% | -71.9% | -36.5% | 5.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.22 | 1.42 | 1.89 |
| Avg | -0.35 | 0.03 | 0.31 |
| Low | -0.68 | -0.72 | -0.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 6,137.6% |
| Avg | - | - | 922.2% |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.